Jild 3 № 1 (2026): Yanvar - Mart
101-108
2026-03-30
Ochiq kirish

Kardiorenometabolik sindromda glp-1 retseptori agonistlarining qo’llanilishi

Eldorbek Nomozov
Nigora Z.Srojidinova
https://doi.org/10.70626/cardiouz-2026-3-00082

Qabul qilingan: 2026-07-08

Nashr etilgan: 2026-03-30

PDF
Crossmark Crossmark

Annotatsiya

Kardiorenometabolik sindrom (KRMS) - zamonaviy tibbiyotning eng muhim muammolaridan biri bo'lib, global miqyosda kasallanish va o'limning yetakchi sabablaridan hisoblanadi. So'nggi besh yil ichida o'tkazilgan yirik randomizatsiyalangan tadqiqotlar -SELECT (2023), FLOW (2024) va STEP-HFpEF (2023) - GLP-1 retseptor agonistlari (GLP-1 RA), xususan semaglutidning yurak-qon tomir va buyrakni himoya qilish mexanizmlari haqida fundamental yangi ma'lumotlarni taqdim etdi. GLP-1 RA larning ta'siri glikemik nazoratdan tashqariga chiqib, endotelial disfunksiya, oksidlovchi stress, NF-κB bog'liq yallig'lanish, RAAS faollashuvi, intraglomerulyar giperfiltratsiya va visseral adipozitetni nishonga oluvchi ko'p komponentli biologik tizimni qamrab oladi. Mavjud klinik va mexanistik dalillar bu sinf preparatlarini kelajakda KRMS boshqaruvining asosiy ustunlaridan biri sifatida ko'rish uchun yetarli asos beradi.

Kalit so‘zlar

Adabiyotlar ro'yxati

  1. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606–1635. https://doi.org/ 10.1161/CIR.0000000000001184.

  2. Khan SS, Ning H, Wilkins JT, et al. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic Syndrome. Circulation. 2023;148(20):1636–1664. https://doi.org/10.1161/CIR.0000000000001186.

  3. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834–1844. https://doi.org/10.1056/NEJMoa1607141.

  4. Mullur N, Morissette A, Morrow NM, Mulvihill EE. GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms. J Endocrinol. 2024;263(1). https://doi.org/10.1530/ JOE-24-0046.

  5. Yang HM. GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies. J Clin Med. 2025;14(19):6758. https://doi.org/10.3390/jcm14196758.

  6. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740–756. https://doi.org/10.1016/j.cmet.2018.03.001.

  7. Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370–7380. https://doi.org/10.1021/acs.jmedchem. 5b00726.

  8. Menghini R, Casagrande V, Rizza S, Federici M. GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform? Acta Diabetol. 2023;60(11):1471–1478. https://doi.org/10.1007/s00592-023-02124-w.

  9. Rajagopal D, Al Rashid S, Prasad M, Fareed M. Unveiling the Potential Role of GLP-1 Receptor Agonists in Offering Protection of the Cardiovascular, Renal, and Neural Systems. Cureus. 2024;16(7):e65910. https://doi.org/10.7759/cureus.65910.

  10. Crajoinas RO, Oricchio FT, Pessoa TD, et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol. 2011;301(2):F355–F363. https://doi.org/10.1152/ajprenal.00729.2010.

  11. Nespoux J, Vallon V. Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future. Acta Diabetol. 2023;61:1–14. https://doi.org/10.1007/s00592-023-02171-3.

  12. Kawanami D, Takashi Y. GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms. Front Pharmacol. 2020;11:967. https://doi.org/10.3389/fphar.2020.00967.

  13. Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20(1):189. https://doi.org/10.1186/s12933-021-01366-8.

  14. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221–2232. https://doi.org/10.1056/NEJMoa2307563.

  15. Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389:1069–1084. https://doi.org/10.1056/ NEJMoa2306963.

  16. Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024;390:1394–1407. https://doi.org/10.1056/NEJMoa2313917.

  17. Tang H, Lu Y, Zhang B, et al. Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study. Diabetes Obes Metab. 2025. https://doi.org/10.1111/dom.70054.

  18. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391:109–121. https://doi.org/10.1056/NEJMoa2403347.

  19. Mahaffey KW, Tuttle KR, Arici M, et al. Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. Eur Heart J. 2024. https://doi.org/10.1093/eurheartj/ ehae613.

  20. Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058–2066. https://doi.org/10.1038/s4 1591-024-03015-5.

  21. Masson W, Lobo M, Nogueira JP, et al. Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis. Front Cardiovasc Med. 2024;11:1379189. https://doi.org/10.3389/fcvm.2024.1379189.

  22. Fathulla HH, Al-Auqbi TFM. GLP-1 Receptor Agonists and Myocardial Perfusion: Bridging Mechanisms to Clinical Outcomes. Biomedicines. 2025;13(4):939. https://doi.org/10.3390/biomedicines13040939.

  23. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4 Suppl):S117–S314. https://doi.org/10.1016/j.kint.2023.10.018.

  24. American Diabetes Association Professional Practice Committee. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S216–S249.

  25. American Diabetes Association Professional Practice Committee. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S246–S265.

  26. Rossing P, Tuttle KR, Perkovic V, et al. Semaglutide and concurrent SGLT2 inhibitor use in people with type 2 diabetes and chronic kidney disease: a pre-specified analysis of the FLOW trial. Lancet Diabetes Endocrinol. 2025;13(2):119–130. https://doi.org/10.1016/S2213-8587(24)00335-6.

  27. Aggarwal R, Ostrominski JW, Vaduganathan M. Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020. JAMA. 2024;331(21):1858–1860. https://doi.org/10.1 001/jama.2024.6892.

  28. International Diabetes Federation. IDF Diabetes Atlas, 11th edition. Brussels: International Diabetes Federation; 2025. https://diabetesatlas.org.

  29. GBD 2023 Chronic Kidney Disease Collaborators. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025. https://doi.org/10.1016/S0140-6736(25)01853-7.

  30. Alieva A, Khaydarova F, Rakhimova G, Ismailov S, et al. Epidemiology of diabetes mellitus and prediabetes in Uzbekistan: screening results. Tashkent; 2018.

Mualliflar haqida

Eldorbek Nomozov
cardiologist0109@gmail.com
Respublika ixtisoslashtirilgan ilmiy-amaliy kardiologiya tibbiyot markazi

Tayanch doktorant

Nigora Z.Srojidinova
nigora5505@gmail.com
Respublika ixtisoslashtirilgan ilmiy-amaliy kardiologiya tibbiyot markazi

Litsenziya

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Qanday iqtibos keltirish kerak

Kardiorenometabolik sindromda glp-1 retseptori agonistlarining qo’llanilishi (E. Nomozov & N. Srojidinova, Trans.). (2026). O’ZBEKISTON KARDIOLOGIYASI, 3(1), 101-108. https://doi.org/10.70626/cardiouz-2026-3-00082
Crossref
Scopus
Google Scholar
Europe PMC

Ushbu muallif(lar)ning eng koʻp oʻqilgan maqolalari

O'xshash maqolalar

Siz ham ushbu maqola uchun {$ advancedSearchLink} olishingiz mumkin.

ISSN 3060-4850 (Print)